Description
Products
32 productsBrand: CinnoRA (40 mg). 40 mg/0.8 mL autoinjector. Rheumatoid arthritis and other inflammatory diseases.
Finished product (FDF)
Verified on 2026-10-21
Brand: Tyalia (40 mg). Intravitreal injection. Wet AMD, diabetic macular oedema, diabetic retinopathy and other eye conditions.
Finished product (FDF)
Verified on 2026-10-21
Brand: Alentiva (50 mg). Antifungal. Severe systemic and/or deep mycoses (disseminated candidiasis, aspergillosis, cryptococcosis, chronic mycetoma, mucormycosis) in adults and children from 1 month.
Finished product (FDF)
Verified on 2026-10-21
Brand: CinnaFact (1 mg). Synthetic peptide GnRH analogue. Endometriosis and infertility treatment.
Finished product (FDF)
Verified on 2026-10-21
Brand: Lixafert (250 mcg). Prevention of premature ovulation in assisted reproductive techniques.
Finished product (FDF)
Verified on 2026-10-21
Brand: Araxya (5 mg). Monoclonal antibody. Metastatic large intestine cancer (alone or in combination, including with encorafenib in BRAF-mutant disease) and head and neck cancer.
Finished product (FDF)
Verified on 2026-10-21
Brand: Acravia (100 mg, 400 mg). Human anti-CD38 monoclonal antibody. Newly diagnosed and relapsed/refractory multiple myeloma.
Finished product (FDF)
Verified on 2026-10-21
Brand: Ablyze (10 mg). Humanized IgG monoclonal antibody binding complement C5. PNH, aHUS, generalized myasthenia gravis and NMOSD.
Finished product (FDF)
Verified on 2026-10-21
Brand: CinnaStim (2000–10000 IU). Syringes. Treatment and prevention of blood clots (peri-operative, immobilisation) and unstable angina.
Finished product (FDF)
Verified on 2026-10-21
Brand: Cinnapoietin (erythropoietin β). Recombinant human erythropoietin produced in CHO cells, prefilled syringes. Anaemia of chronic kidney disease, autologous blood pre-donation and prevention of anaemia of prematurity.
Finished product (FDF)
Verified on 2026-10-21
Brand: Eldona (140 mg). Monoclonal antibody. Reduction of major adverse cardiovascular events in high-risk adults and hyperlipidaemia.
Finished product (FDF)
Verified on 2026-10-21
Brand: Nowaria (300 mcg/0.5 mL prefilled syringe). Chemotherapy-induced myelosuppression, AML, bone marrow transplantation, acute radiation syndrome and progenitor cell mobilisation.
Finished product (FDF)
Verified on 2026-10-21
Brand: Cinnal-f (75, 150, 300, 450, 900 IU). Prefilled pen. Ovarian stimulation, assisted reproductive technology and anovulation (with lutropin alfa).
Finished product (FDF)
Verified on 2026-10-21
Brand: Cinnomer (20, 40 mg). Relapsing forms of multiple sclerosis.
Finished product (FDF)
Verified on 2026-10-21
Brand: Eldixia (100 mg). Human IgG1 monoclonal antibody in prefilled syringe. Moderate to severe plaque psoriasis in adults.
Finished product (FDF)
Verified on 2026-10-21
Brand: Gylava (100 IU). Diabetes mellitus in adults, adolescents and children aged 2 and above.
Finished product (FDF)
Verified on 2026-10-21
Brand: ReciGen (22, 44, 132 mcg). Prefilled syringe. Relapsing forms of multiple sclerosis.
Finished product (FDF)
Verified on 2026-10-21
Brand: CinnoVex (30 mcg). Relapsing multiple sclerosis.
Finished product (FDF)
Verified on 2026-10-21
Brand: Herozyme (580 mcg). Enzyme replacement. Non-neurological manifestations of mucopolysaccharidosis type I (MPS I).
Finished product (FDF)
Verified on 2026-10-21
Brand: Melitide (6 mg/mL). GLP-1 analogue. Type 2 diabetes in adults and children aged 10+ and cardiovascular risk reduction.
Finished product (FDF)
Verified on 2026-10-21
Brand: Maciza (6 mg/mL; 18 mg/3 mL pen). GLP-1 analogue. Weight management in adults with obesity or overweight with comorbidity.
Finished product (FDF)
Verified on 2026-10-21
Brand: Xtramab (40, 100, 240 mg). Fully human IgG4 anti-PD-1 monoclonal antibody. Melanoma, NSCLC and other cancers.
Finished product (FDF)
Verified on 2026-10-21
Brand: Xacrel (30 mg). Humanized anti-CD20 monoclonal antibody. Relapsing and primary progressive multiple sclerosis.
Finished product (FDF)
Verified on 2026-10-21
Brand: Zerafil (150 mg). Anti-IgE monoclonal antibody. Moderate to severe persistent allergic asthma, chronic spontaneous urticaria and other indications.
Finished product (FDF)
Verified on 2026-10-21
Brand: KidiPeg. 3 mg/0.3 mL prefilled syringe (product list shows "10, 50 mg"). Decreases infection (febrile neutropenia) in non-myeloid malignancies on myelosuppressive therapy.
Finished product (FDF)
Verified on 2026-10-21
Brand: PegaGen (6 mg). Prevention of chemotherapy-induced neutropenia.
Finished product (FDF)
Verified on 2026-10-21
Brand: ZakAria (25 mg). Humanized anti-PD-1 monoclonal antibody. Melanoma, Merkel cell carcinoma, lung, head and neck cancer, lymphomas and other cancers.
Finished product (FDF)
Verified on 2026-10-21
Brand: Pectuna (30 mg). Anti-HER2 monoclonal antibody. Early and metastatic breast cancer.
Finished product (FDF)
Verified on 2026-10-21
Brand: SpikoGen (25 mcg). Recombinant SARS-CoV-2 Spike protein with Advax-SM adjuvant, produced in cooperation with Vaxine (Australia). Primary vaccination and booster.
Other
Verified on 2026-10-21
Brand: CinnaTropin (4, 10, 20 IU). Recombinant growth hormone in prefilled pen. Growth failure due to GH deficiency, Turner syndrome and other paediatric indications.
Finished product (FDF)
Verified on 2026-10-21
Brand: CinnoPar (250 mcg); Zandoriah in the EU. Recombinant human parathyroid hormone analogue, biosimilar to Forsteo. Postmenopausal, male and glucocorticoid-induced osteoporosis at high fracture risk.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Spartina (2.5–15 mg). Type 2 diabetes and weight loss and maintenance in adults.
Finished product (FDF)
Verified on 2026-10-21